TPSi launches pharma opinion leaders panel
The FutureThinker Panel is made up of 1,000 influential clinicians from the US, the UK, Germany, France, Italy and Spain, selected using a psycho-profiling tool developed by the firm.
The firm said it is working with one of the largest pharmaceutical database suppliers to expand the panel.
TPSi managing director Kim Hughes said: “The FutureThinker Panel is an exciting initiative that will allow pharmaceutical companies to develop strategy and prioritise tactics based on the feedback of these highly influential opinion formers.”
We hope you enjoyed this article.
Research Live is published by MRS.
The Market Research Society (MRS) exists to promote and protect the research sector, showcasing how research delivers impact for businesses and government.
Members of MRS enjoy many benefits including tailoured policy guidance, discounts on training and conferences, and access to member-only content.
For example, there's an archive of winning case studies from over a decade of MRS Awards.
Find out more about the benefits of joining MRS here.
0 Comments